US stock · Healthcare sector · Biotechnology

Arena Pharmaceuticals, Inc.

ARNA

NASDAQ

99.99

USD

- -

(- -)

Market Closed

-9.96P/E

- -Forward P/E

-0.38P/E to S&P500

- -MMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

- -

Shares Short

Short % of Float

- -

Short % of Shares Outs.

- -

% Held by Insiders

- -

% Held by Institutions

- -

Beta

0.55

PEG Ratio

- -

52w. high/low

- -/- -

Avg. Daily Volume

1.47M

Return %

Stock

S&P 500

1 year

46.01

(1.30)

3 years

122.45

40.60

5 years

629.85

72.91

Scale: |

High

Low

147.80

77.60

86.80

27.00

74.20

22.60

80.00

12.60

26.20

12.10

135.00

15.10

110.00

40.50

79.70

32.60

62.80

16.00

21.60

13.00

35.09

11.30

50.05

30.00

64.48

38.18

90.19

32.95

94.08

45.53

100.00

89.05

Currency: USD

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

Revenue per share

6.54

3.08

1.33

1.23

1.52

0.91

1.40

3.73

1.68

1.59

5.10

0.65

0.38

16.20

0.01

0.00

Earnings per share

(18.45)

(22.80)

(32.17)

(18.16)

(11.37)

(7.85)

(4.35)

(0.89)

(2.75)

(4.49)

(0.93)

(2.77)

(0.62)

7.99

(7.39)

(11.26)

FCF per share

(18.23)

(23.19)

(31.72)

(19.12)

(5.16)

(5.67)

(2.33)

2.92

(5.02)

(4.53)

(2.59)

(2.02)

(2.83)

11.33

(6.46)

(9.55)

Dividends per share

- -

CAPEX per share

3.04

2.78

5.79

0.63

0.38

0.04

0.09

0.42

0.41

0.46

0.04

0.00

0.01

0.10

0.01

1.30

Book Value per sh.

78.31

53.58

15.93

8.84

7.30

0.76

5.02

4.21

2.15

2.22

1.64

6.28

12.89

21.52

19.73

12.29

Comm.Shares outs.

Avg. annual P/E ratio

(7.6)

(5.2)

(1.8)

(2.3)

(3.0)

(2.0)

(14.7)

(81.2)

(19.7)

(8.0)

(17.9)

(7.3)

(64.1)

6.3

(8.2)

(5.9)

P/E to S&P500

(0.4)

(0.3)

(0.1)

(0.0)

(0.1)

(1.0)

(4.8)

(1.1)

(0.4)

(0.8)

(0.3)

(2.6)

0.3

(0.2)

Avg. annual div. yield

- -

Revenue (m)

124

806

Operating margin

(303.6)%

(818.8)%

(2,405.2)%

(1,332.3)%

(580.0)%

(651.0)%

(207.0)%

(28.2)%

(284.8)%

(269.3)%

(13.8)%

(431.0)%

(805.7)%

59.9%

(133,742.6)%

(1,156,109.3)%

Depreciation (m)

Net profit (m)

(86)

(143)

(238)

(153)

(125)

(109)

(85)

(19)

(61)

(108)

(23)

(91)

(29)

398

(405)

(616)

Income tax rate

- -

79.4%

21.7%

- -

Net profit margin

(282.1)%

(740.6)%

(2,422.0)%

(1,475.0)%

(749.6)%

(858.7)%

(309.8)%

(23.9)%

(163.7)%

(281.7)%

(18.2)%

(428.4)%

(163.6)%

49.3%

(126,875.9)%

(1,141,542.6)%

Working capital (m)

364

379

101

120

141

178

115

125

209

431

715

1,081

503

Long-term debt (m)

- -

Equity (m)

366

336

118

207

606

1,071

1,080

673

ROIC

- -

(33.0)%

(4.6)%

(25.6)%

(48.9)%

(15.3)%

(31.9)%

(4.2)%

35.5%

(35.3)%

(85.2)%

Return on capital

(18.0)%

(29.4)%

(98.4)%

(56.9)%

(38.6)%

(60.4)%

(29.2)%

(3.6)%

(19.4)%

(39.4)%

(9.5)%

(25.1)%

(19.5)%

43.7%

(33.6)%

(78.0)%

Return on equity

(23.6)%

(42.6)%

(202.0)%

(205.5)%

(155.6)%

(1,034.1)%

(86.7)%

(21.2)%

(127.8)%

(201.7)%

(56.4)%

(44.1)%

(4.8)%

37.1%

(37.5)%

(91.6)%

Plowback ratio

100.0%

Div.&Repurch./FCF

- -

(2.3)%

- -

Capital Structure

23 Feb · 2022 | Q4

All numbers in millions

Total liabilities

$ 111

Total assets

$ 785

Long-term debt

$ 36

Cash and equiv.

$ 225

Goodwill

$ - -

Retained earnings

$ (2,124)

Common stock

Enterprise Value

$ - -

Working Capital

Currency: USD, in millions

2019

2020

2021

Cash & Investments

740

1,104

550

Receivables

- -

Inventory

- -

Other

Current assets

760

1,139

569

Acc. Payable

Debt due

Other

Current liabilities

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

(83.07)%

1,047.21%

497.07%

Cash flow

47.78%

(135.04)%

(121.09)%

Earnings

52.31%

(417.40)%

(136.70)%

Dividends

- -

Book value

(37.69)%

58.14%

64.88%

Insider Trading

Type

Date

Neil Garry Arthur

Return

7,202

03/11/22

Neil Garry Arthur

Other

3,067

03/11/22

Neil Garry Arthur

Other

8,150

03/11/22

Jarrett Jennifer

Return

7,202

03/11/22

Jarrett Jennifer

Other

3,067

03/11/22

Quarterly Revenue

Currency: USD, in millions

Year

Total

2019

801

806

2020

- -

2021

- -

Earnings per share

Currency: USD

Year

Total

2019

12.46

(1.23)

(1.46)

(1.77)

7.99

2020

(1.83)

(1.55)

(1.78)

(2.23)

(7.39)

2021

(2.16)

(2.67)

(3.58)

(2.84)

(11.26)

Quarterly dividends paid

Currency: USD

Year

Total

2019

- -

2020

- -

2021

- -

Company Description

Sector:

Healthcare

Industry:

Biotechnology

CEO:

Mr. Amit Munshi

Full-time employees:

448

City:

San Diego

Address:

6154 Nancy Ridge Dr

IPO:

Jul 28, 2000

CIK:

0001080709

Website:

arenapharm.com

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Powered by AI

Arena Pharmaceuticals, Inc.

99.99